Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Carfilzomib Achieves 26 Percent Clinical Benefit Response Rate in Phase 2 Trial of Relapsed and Refractory Multiple Myeloma
Patients - Proteolix Expands Trial
ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- Proteolix, Inc. today presented results from the company's most ...
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression
NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced updated clinical results from an ongoing Phase 1/2...
Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology
Company today reported updated results from two large, multi-center,
randomized Phase III clinical trials of VELCADE based combinations for the
induction treatment of transplant-eligible patients with previously untreated
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
SAN FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The Takeda Oncology
Company today reported the Phase I results from a randomized, multi-center,
Company-sponsored Phase I/II study of VELCADE, dexamethasone, cyclophosphamide
and lenalidomide (VcDCR) in patients with previously untreated multiple
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
- Patients in the VELCADE, melphalan and prednisone arm demonstrated a
significant survival benefit as well as a 30 percent complete response -
CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Millennium: The Takeda
Oncology Company today announced the publication of results from the 682
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
-- Recommendation based on study results demonstrating survival advantage of 18.4 months when added to standard therapy
-- First study to show survival advantage over European standard of care
BOULDER, Colo., Jan. 24 /PRNewswire-FirstCall/ -- Pharmion Corporation
(Nasdaq: PHRM ) ...
Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Dr. Paul Richardson presents Phase 1 results demonstrating clinical activity of perifosine in combination with bortezomib in patients
previously treated with bortezomib, and provides an update on an ongoing Phase 2 study of perifosine in combination with dexamethasone
NEW YORK, Dec. ...
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
HAYWARD, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Kosan Biosciences
Incorporated (Nasdaq: KOSN ) presented updated data from a dose-escalating
Phase 1b clinical trial of Hsp90 inhibitor tanespimycin (KOS-953) in
combination with bortezomib (Velcade(R)), showing durable antitumor
activity and ...
Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
WASHINGTON, Nov. 1 /PRNewswire-USNewswire/ -- Multiple myeloma
of the most common and devastating bone marrow cancers in the U.S., but
survival rates have risen dramatically over the past decade. Recent
analyses suggest that this trend may be attributed to new types of drugs
Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
ANN ARBOR, Mich. Sept. 24 /PRNewswire/ -- Velcura Therapeutics, Inc., a
biotechnology company developing therapies for bone disease, met with the
U.S. Food and Drug Administration (FDA) Sept. 20 to clarify details for the
early clinical development of VEL-0230, a drug developed to treat bone
The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
WHITE PLAINS, N.Y., Sept. 18 /PRNewswire/ -- Millennium Pharmaceuticals
and Johnson & Johnson have reported that an interim analysis of a large,
randomized, international Phase III trial comparing melphalan-prednisone
(MP) with MP in combination with Velcade(R) (bortezomib) showed that the
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
- Millennium on track to file sNDA in first quarter 2008 -
CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced that the interim
analysis results of the large, international Phase III VISTA(1) trial in
patients with newly...
September is Leukemia, Lymphoma and Myeloma Awareness Month
Tremendous advances have been made to treat blood cancer but the battle is far from won
WHITE PLAINS, N.Y., Sept. 12 /PRNewswire/ -- Remarkable progress has
been made in treating patients with blood cancers. Sixty years ago there
were few effective treatments for ch...
Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Multi-Center International Study to Determine the Efficacy of LBH589 in Patients with Relapsed or Refractory Multiple Myeloma
NORWALK, Conn., Aug. 14 /PRNewswire-USNewswire/ -- The Multiple Myeloma
Research Consortium (MMRC) today announced its participation in a Phase II
study to dete...
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Phase 2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 15 /PRNewswire/ --
The Multiple Myeloma
Research Consortium (MMRC) and Proteolix, Inc. today
XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
REHOVOT, Israel, March 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals
Ltd. (Nasdaq: XTLB ; TASE: XTL) announced today that it has entered into an
asset purchase agreement with Bio-GAL Ltd, a private company, for the rights
to a use patent on Recombinant Erythropoietin ("rHuEPO") for the...
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results based on extended follow up of patients from the large, international Phase III VISTA(1) trial showing continued survival improvement for patients with previously untreated multiple myeloma...
Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
- First of three ongoing randomized chemotherapy combination trials to evaluate HGS-ETR1 in the treatment of specific cancers -
ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome
Sciences, Inc. (Nasdaq: HGSI ) today reported initial topline results from
an ongoing randomiz...
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
Provides Update on Carfilzomib Development Program in Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc.
today announced that patient dosing has commenced in a Phase 1b clinical
trial to evaluate the safety and efficacy of Proteolix's lead anti-cancer
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda
Oncology Company, today announced the presentation of results from three
clinical trials of VELCADE based therapies that showed consistently high
complete remission(1) (CR) rates in patients with newly diagnosed multiple
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
-- IFM presents updated results from Phase III clinical trial --
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda
Oncology Company, today announced the presentation of updated results from
a 482 patient, multi-center, randomized Phase III clinical trial, comparing
New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
- Five Oral Presentations at ASCO Annual Meeting Will Further Demonstrate
the Strength of VELCADE Combinations in Front-line Multiple Myeloma
CAMBRIDGE, Mass., May 16 /PRNewswire/ -- Millennium Pharmaceuticals,
The Takeda Oncology Company, today announced that new data from VELCADE
Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
SAN DIEGO, April 14 /PRNewswire/ -- Semafore Pharmaceuticals Inc.
announced today on the occasion of a poster presentation at the 2008 AACR
Annual Meeting that its integrin-targeted PI3 kinase inhibitor, SF1126, was
shown to cause significant tumor regression in combination with rapamycin
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
- Three large, randomized Phase III trials of VELCADE in front-line
to be featured as oral presentations at the American Society of Hematology (ASH) Annual Meeting -
CAMBRIDGE, Mass., Nov. 26 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq:...
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Tanespimycin is the First Hsp90 Inhibitor to Enter Registration Trials
HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences
Incorporated (Nasdaq: KOSN ) today announced that it has successfully
reached a binding agreement with the U.S. Food and Drug Administration
(FDA) on th...
Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Tanespimycin is Industry's First Hsp90 Inhibitor to Enter Registration Program TIME Registration Program Utilizes New, Proprietary Tanespimycin Formulation
HAYWARD, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Kosan Biosciences
Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
-- U.S.-based trial to evaluate four-drug therapy containing highly active and novel multiple myeloma
CAMBRIDGE, Mass., Aug. 15 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced the initiation of a
randomized, multi-center, Co...
Gemin X Announces Publication of Preclinical Data of GX15-070 in
Multiple Myeloma in Blood
MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Mar 7, 2007 - Gemin X
announced today that a report published in the online version of
the journal Blood demonstrated that its lead compound, GX15-070
(obatoclax), induced potent cytotoxic responses against
patient-derived multiple myeloma
tumor cells a...
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03)
Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival
Advantage for Patients with Multiple Myeloma
SUMMIT, N.J., April 04, 2007 /PRNewswire-FirstCall/ -- Celgene
Corporation announced that the Eastern Cooperative Oncology Group
(ECOG) has reported that its Data Monitoring Committee's (DMC)
review of preliminary results from a large, randomized clinical
trial for patients with newly diagnosed mu...
The International Myeloma Foundation Says New Clinical Trial
Results Could Improve Survival While Reducing Side Effects For Many
- Findings Show Survival Improvement with Lower Doses of
Dexamethasone, the Steroid Commonly Used with REVLIMID and other
Drugs in Newly Diagnosed Myeloma
NORTH HOLLYWOOD, Calif., April 04, 2007 /PRNewswire/ -- The
Foundation (IMF) - supporting research and
Low-Dose Steroid Combined With Lenalidomide Prolongs Survival
Compared With High-Dose Steroid for Multiple Myeloma Treatment
WASHINGTON, April 4, 2007-Preliminary results from a large,
randomized clinical trial for patients with newly diagnosed
multiple myeloma, a cancer typically found in bone marrow, has
shown that the use of a low dose of the steroid dexamethasone
(Decadron ®), in combination with lenalidomide (Re...
Sunesis Presents Data Supporting SNS-032's Potential Anticancer
Activity in Multiple Myeloma at the American Association for Cancer
Results from Non-clinical Studies Confirm Mechanism of Action and
Provide Guidance for Dosing
SOUTH SAN FRANCISCO, April 16, 2007 /PRNewswire-FirstCall/ --
Sunesis Pharmaceuticals, Inc. presented non-clinical data
demonstrating SNS-032's apoptotic activity in a multiple myeloma
model. These data w...
The International Myeloma Foundation Reports Positive Shift In
Treatment Paradigm For Patients
-Second Closure of Multi-Center Trial in 4 Weeks Reinforces
Benefits of Using REVLIMID with Low Dose Steroids in Myeloma-
NORTH HOLLYWOOD, Calif., May 15, 2007 /PRNewswire/ -- The
Foundation (IMF) - supporting research and
providing education, advocacy and support for myeloma...
Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing
Promising Antitumor Activity in Multiple Myeloma at ASCO
Tanespimycin TIME Registration Program to Begin Third Quarter 2007
HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan
Biosciences Incorporated presented data from a dose-escalating
Phase 1b clinical trial of its lead Hsp90 inhibitor, tanespimycin
(KOS-953) in combination with bortezomi...
Adding Thalidomide to Standard Therapy Improves Survival in Newly
Diagnosed Multiple Myeloma Patients Over Age 75
Phase III Clinical Data on Thalidomide in Multiple Myeloma
Presented at the American Society of Clinical Oncology 43rd Annual
CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion
Corporation today reported the final results of a Phase III study
demonstrating that the addition of Thali...
Velcade (bortezomib) for Injection Survival Data in Front-Line
Multiple Myeloma Patients to be Featured at 11th International
-- More than 70 abstracts highlight VELCADE efficacy in broad range
of patients and across continuum of care --
CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ --
Millennium Pharmaceuticals, Inc. today announced that data for
VELCADE, the market leading therapy with unsurpassed single-agent...
ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical
KOS, Greece--(BUSINESS WIRE)--Jun 26, 2007 - Acceleron Pharma,
Inc., a biopharmaceutical company developing therapeutics for the
treatment of musculoskeletal, metabolic and cancer-related
diseases, today announced results demonstrating that ACE-011, a
novel anabolic bone agent for the treatment of ...
Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Quadramet at International Myeloma Workshop
PRINCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Cytogen
Corporation (NASDAQ: CYTO) reported updated data from a Phase 1
dose escalation study evaluating QUADRAMET(R) (samarium Sm-153
lexidronam injection) in combination with bortezomib (Velcade(R),
Millennium Pharmaceuticals, Inc.) in patients wit...
ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data
Presented at International Myeloma Workshop
KOS, Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM Oncology,
Inc. (NASDAQ: ZIOP), announced today the presentation of two
posters at the XIth Annual International Myeloma
held in Kos, Greece from June 25-28th, 2007. The meeting highlights
important advances made in the biology and...
The International Myeloma Foundation Says Data Reported at a Global
Medical Meeting in Greece Demonstrates Improved Survival for a Wide
Range of Myeloma Patients
- Data Presented at the 11th International Myeloma
NORTH HOLLYWOOD, Calif., and KOS, Greece, June 29, 2007
/PRNewswire/ -- The International Myeloma
Foundation (IMF) --
supporting research and providing education, advocacy and support
patients, families, researchers and phys...